Published in final edited form as:

J Med Chem. 2010 October 14; 53(19): 7229–7235. doi:10.1021/jm100946e.

Synthesis and Evaluation of Selected Key Methyl Ether Derivatives of Vancomycin Aglycon

Christine M. Crane[†], Joshua G. Pierce[†], Siegfried S. F. Leung^{‡,a}, Julian Tirado-Rives[‡], William L. Jorgensen[‡], and Dale L. Boger^{†,*}

[†] Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

[‡] Department of Chemistry, Yale University, 225 Prospect Street PO Box 208107, New Haven, Connecticut, 06520-8107

Abstract

A select series of methyl ether derivatives of vancomycin aglycon were prepared and examined for antimicrobial activity against vancomycin-sensitive *Staphylococcus aureus* and vancomycin-resistant *Enterococci faecalis*, as well as their binding affinity for D-Ala-D-Ala and D-Ala-D-Lac. The intent of the study was to elucidate the role selected key methyl groups may play in the improvement of *in vitro* antimicrobial profile of the tetra methyl ether derivative of vancomycin aglycon against vancomycin-resistant *Enterococci faecalis* previously reported. In these studies, methodology for selective derivatization of the A-, B-, and D-ring was developed that defines the relative reactivity of the four phenols of vancomycin aglycon, providing a foundation for future efforts for site-directed modification of the vancomycin aglycon core.

Introduction

Vancomycin (**1**) is the antibiotic of last resort used to treat Gram-positive bacterial infections, especially those caused by methicillin-resistant *Staphylococcus aureus* and for patients allergic to β -lactam antibiotics. Vancomycin's biological activity arises from its ability to bind to the terminal L-Lys-D-Ala-D-Ala portion of the bacterial cell wall peptidoglycan precursor, preventing transpeptidase-catalyzed cross-linking and maturation of the bacterial cell wall.¹ An inducible vancomycin-resistance pathway has evolved in *Enterococci* bacterial strains (VanAb and VanB) that is now beginning to emerge in *Staphylococcus aureus* (*S. aureus*),^{1e-f} whereby the C-terminal amino acid is modified from D-alanine to D-lactic acid (Figure 1).^{1,2} This single atom modification (NH $\rightarrow$ O) reduces the affinity of **1** for the cell wall peptidoglycan precursor 1000-fold rendering the antibiotic ineffective, with a corresponding 1000-fold drop in antimicrobial activity.^{1d} This loss of affinity and antimicrobial activity can be attributed to both the loss of a key H-bond and the introduction of lone pair repulsive interactions between the residue 4 carbonyl of vancomycin and the ester oxygen of the D-Lac on the C-terminus of the ligand.^{3,4} The

*To whom correspondence should be addressed. Phone: 858-784-7522. Fax: 858-784-7550. boger@scripps.edu.

^aPresent address: Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158

Supporting Information Available: Compounds **2** and **6** were prepared according to published procedures.^{7,15} Full experimental details, characterization for all new intermediates and final compounds, and 2D-ROESY for all final compounds are provided in the supporting information. This material is available free of charge via the Internet at <http://pubs.acs.org>.

^bAbbreviations: VanA, vancomycin/teicoplanin type-A resistant; VanB, teicoplanin-sensitive and vancomycin type-B resistant; VRE, vancomycin-resistant *Enterococci*; H-bond, Hydrogen bond; D-Lac, D-Lactic acid; TFA, trifluoroacetic acid; Pd/C, Palladium on activated Carbon; MIC, minimum inhibitory concentration.

former contributes no more than 10-fold and the latter at least 100-fold to the experimentally observed 1000-fold loss in affinity for the ligand.^{3,4}

Significant efforts have been directed towards the discovery of next-generation glycopeptide antibiotics that address the emerging vancomycin resistance.^{5–11} Numerous modifications have been introduced to the natural product that have improved the *in vitro* antimicrobial activity of these vancomycin derivatives against vancomycin-sensitive and resistant strains.^{5–8} In our own efforts and complementary to semi-synthetic modifications of key residues,^{7,8} the offending residue 4 carbonyl of the natural product was removed and provided [Ψ [CH₂NH]Tpg⁴]vancomycin aglycon (**5**), a compound prepared by total synthesis, which exhibited significantly improved activity against resistant VanA bacteria and dual binding properties for both peptidoglycan analogues *N,N'*-Ac₂-L-Lys-D-Ala-D-Ala (**3**) and *N,N'*-Ac₂-L-Lys-D-Ala-D-Lac(**4**), (Figure 2).^{4a}

In the course of these and related efforts, and initially enlisting derivatives of key synthetic intermediates,^{4c} we found that derivatives of vancomycin aglycon (**2**), in which each of the four phenols were protected as methyl ethers (Figure 3), exhibited effective antimicrobial activity against both vancomycin sensitive and resistant bacteria (Figure 4). In further exploring the activity, we found that such hydrophobic derivatives of vancomycin aglycon (e.g. **6–7**) exhibited equipotent antimicrobial activity against the sensitive and VanB resistant bacteria (Figure 4), and displayed improved activity against VanA bacteria, without possessing significantly altered binding affinity for model ligands **3** and **4**.^{7,8} This profile of activity is identical, but less potent than that of chlorobiphenyl vancomycin^{1a,6} (**8**), and the related analogue oritavancin (LY333328)^{5,12} and teicoplanin (**9**),⁷ which bear hydrophobic side chains on the saccharides attached to the phenol of the central residue (Figure 4). Impressively, analogous methyl ether derivatization of the teicoplanin or ristocetin aglycons similarly provided equipotent antimicrobial activity against sensitive and VanB resistant bacteria establishing the generality of the observations.⁷ Notably, derivatives such as **6–7** lack a lipid side chain and a disaccharide suggesting that membrane anchoring¹³ and transglycosylation inhibition¹⁴ effects invoked for teicoplanin and **8** may not account for the origin of the effects with **6**. In an extension of this work and in concert with computational studies,¹¹ we sought to further define the role methyl substitution of the phenols plays in contributing to these properties. Most notable in the computational studies was the generalized trend for a residue 7 C3 methoxy (vs phenol hydroxy, R² herein, Figure 3) substituent to improve binding to both D-Ala-D-Ala and D-Ala-D-Lac, whereas analogous changes at C5 (R⁴ herein, Figure 3) were benign, and those at residue 5 at C4 (R³ herein, Figure 3) were counterproductive to D-Ala-D-Lac binding. Especially attractive was the projected binding characteristics of compound **10** (R¹ = R³ = H, R² = R⁴ = Me, Figure 3) that was computed to improve affinity for D-Ala-D-Ala by 1.2 kcal/mol and D-Ala-D-Lac by 1.7 kcal/mol. Consequently, compound **10** and its comparison dimethyl ether isomer **11** were of special interest to us to examine. For this purpose, selective derivatization of the phenols was established and provided a key set of mono-, bis-, and tris-methyl ethers **10–13** (Figure 3) and both the association constants (*K_a*) for the ligands **3** and **4** as well as their *in vitro* antimicrobial activity established. Significantly, a sequential reactivity order (Figure 3) for the four phenols of the vancomycin aglycon was established that will permit additional future semi-synthetic modifications.

Chemistry

Vancomycin aglycon **2** was prepared according to a modified literature procedure by TFA-mediated deglycosylation of **1** in the presence of excess anisole (Scheme 1).¹⁵ Boc-protection followed by benzyl ester formation (2 equiv BnBr, NaHCO₃, DMF, 25 °C, 18 h, 47%) provided **14**. The use of NaHCO₃ (vs Na₂CO₃) allows for selective esterification of

the carboxylic acid, whereas stronger inorganic bases led to competitive phenol alkylation. However, the yields of ester **14** were significantly lower if more than two equivalents of BnBr was used, as competing mono-benzyl ether formation of the D-ring phenol was observed even with NaHCO₃ to provide **15** (Scheme 1). Subsequent, deliberate stepwise alkylation of **14** (1 equiv BnBr, 2 equiv K₂CO₃, DMF, 25 °C, 18 h) provided the D-ring monobenzyl ether **15** (42%), and a mixture of bis-benzyl ethers **16** and **17** (25%, Scheme 1) resulting from D-ring benzyl ether formation followed by A- or B-ring benzyl ether formation. The mixture of bis-benzyl ethers **16** and **17** could also be obtained from deliberate benzylation of **15** (1 equiv BnBr, 2 equiv K₂CO₃, DMF, 25 °C, 18 h) in 56% yield (providing a 2:1 mixture of **16/17**), without additional over benzylation products being isolated. The above result defines a stepwise order of alkylation of the phenols of vancomycin aglycon that is depicted in Figure 3, and this was also observed when methyl iodide was used as the alkylating agent (data not shown).

The mixture of **16** and **17** (2:1 regioselectivity, respectively) was separated and the assignment for each structure was conducted by 2D-ROESY (Figure 5). Compound **16** displayed diagnostic Nuclear Overhauser Enhancement (NOE) cross-peaks between the unalkylated phenol protons of the A-ring (OHa and OHb) to their respective adjacent aromatic protons (H¹ and H²) one of which they share (H²), and the benzylic protons of the B-ring benzyl ether (CH₂b) exhibited a diagnostic NOE cross-peak with its adjacent aromatic proton H³ on the B-ring (Figure 5a, for the 2D-ROESY of **16** see the Supporting Information Figure 1SI). Conversely, compound **17** displayed NOE cross-peaks between the unalkylated phenol proton of the A-ring (OHa) to its respective adjacent aromatic protons (H¹ and H²), the benzylic protons of the A-ring benzyl ether exhibited a diagnostic NOE cross-peak with its adjacent shared aromatic proton H² on the A-ring, and the unalkylated phenol of the B-ring displayed a diagnostic NOE cross-peak to its adjacent buried aromatic H³ proton (Figure 5b, for 2D-ROESY of **17** see the Supporting Information Figure 2SI). Subsequent global methylation of **16** (40 equiv methyl iodide, 10 equiv K₂CO₃, DMF, 25 °C, 18 h) provided the fully alkylated derivative **18** in 54% yield (Scheme 2). Global methylation of regioisomer **17** proved more challenging and in the end required additional methyl iodide (60 equiv) to provide the desired fully alkylated intermediate **19**. Subsequent hydrogenolysis of the benzyl ethers and benzyl ester of **18** and **19** using H₂ (g) over 10% Pd/C (EtOH/EtOAc, 25 °C, 4–16 h) followed by acidic removal of the Boc-group with TFA in methylene chloride (1:9, 25 °C, 15 min) provided the target molecules **10** and **11** as their trifluoroacetic acid (TFA) salts after RP-HPLC purification, in 81% and 56% yield, respectively (Scheme 2, for 2D-ROESY data see the Supporting Information Figures 3SI-4SI).

Tris-methyl ether derivative **12** was prepared starting from **15** (Scheme 3). Methylation of the remaining phenols (40 equiv methyl iodide, 10 equiv K₂CO₃, DMF, 25 °C, 18 h) provided **20** in 58% yield. Intermediate **20** was debenzylated (H₂, 10% Pd/C, EtOH/EtOAc, 25 °C, 3–16 h) then treated with TFA/CH₂Cl₂ (1:9, 25 °C, 15 min) to afford **12** as its TFA salt after HPLC purification in 62% yield (For 2D-ROESY data see the Supporting Information Figure 5SI).

In a similar manner, the D-ring mono methyl ether **21** (Scheme 4) was prepared by mono methylation of the D-ring of **14** (1 equiv methyl iodide, 2 equiv K₂CO₃, DMF, 25 °C, 18 h). Subsequent hydrogenolysis of the benzyl ester (H₂, 10% Pd/C, EtOH/EtOAc, 25 °C, 3–16 h), and removal of the Boc group (TFA/CH₂Cl₂, 25 °C, 15 min) provided the D-ring methyl ether **13** as its TFA salt in 82% yield after HPLC purification (for 2D-ROESY data see the Supporting Information Figure 6SI).

Results and Discussion

The antimicrobial properties of **10–13** were determined against a vancomycin-sensitive *Staphylococcus aureus* (*S. aureus*, strain ATCC 25923), a vancomycin-resistant and teicoplanin-sensitive (VanB) *Enterococcus faecalis* (*E. faecalis*, strain ATCC 51299), and a vancomycin- and teicoplanin-resistant (VanA) *E. faecalis* (strain BM4166) in a microtiter plate-based antimicrobial assay (Table 1).^{4,7,8} The VanB strain (ATCC 51299) and the latter VanA strain (BM4166) possess a vancomycin (**1**) inducible resistance pathway that becomes operative upon treatment with glycopeptide antibiotics. VanA and VanB utilize D-Ala-D-Ala peptidoglycan cell wall precursors when left unchallenged, but will switch to D-Ala-D-Lac peptidoglycan cell wall precursors upon treatment with a glycopeptide. The association constants (K_a) for ligands **3** and **4** and free energies of binding ($\Delta\Delta G_b$) for compounds **10–13** were determined using a well-established UV-difference titration assay.¹⁶ The experimentally determined K_a was then used to calculate $\Delta\Delta G_b$'s, which were then compared to those determined computationally (Table 2).^{7,8,11,16} For an representative saturation binding curve with **3** and **4** and subsequent Scatchard analysis see the Supporting Information (Figures 7SI–8SI).

The compounds exhibited an interesting range of activity in the antimicrobial assays against the sensitive and the resistant bacteria. Whereas the aglycon **2** containing all four free phenols and the permethylated derivative **6** containing four methyl ethers were equally potent against the sensitive *S. aureus* strain (MIC = 1.25 $\mu\text{g/mL}$, strain ATCC 25923), partial methylation of the phenols led to significant losses in activity. Only **13**, bearing a single methyl ether on the D-ring phenol matched the activity of **2** and **6**, whereas the trimethyl ether **12** and the two isomeric dimethyl ethers **10** and **11** experienced 4-fold and 8-fold losses in activity, respectively. Their activity against the resistant VanB strain of *E. faecalis* (strain ATCC 51299) was even more striking and, with the exception of the vancomycin aglycon **2** itself, displayed a similar trend. The mono methyl ether **13** bearing a D-ring methyl ether, like **2** itself, was relatively inactive against this VanB strain (MIC = 40–80 $\mu\text{g/mL}$), and the two isomeric dimethyl ethers **10** and **11** were even less active (MIC = 120 $\mu\text{g/mL}$). In contrast, the activity improved substantially with **12** bearing three methyl ethers (MIC = 10 $\mu\text{g/mL}$), and the tetramethyl ether **6** exhibited a potency (MIC = 2.5 $\mu\text{g/mL}$) essentially equivalent to its activity against sensitive *S. aureus*.

Especially interesting was the behavior against a resistant *E. faecalis* VanA strain (BM4166). This strain, which is resistant to teicoplanin (MIC >100 $\mu\text{g/mL}$) and is also 100-fold resistant to chlorobiphenyl vancomycin **8** (10 $\mu\text{g/mL}$ for VanA vs 0.03 $\mu\text{g/mL}$ for sensitive strain), was resistant to not only vancomycin aglycon (**2**, MIC = 640 $\mu\text{g/mL}$), but to **10–12** as well. However, it exhibited sensitivity to **13**, albeit at a modest level (MIC = 240 $\mu\text{g/mL}$), and exhibited the significantly increased sensitivity with only **6** (MIC = 80 $\mu\text{g/mL}$). Like **8** and teicoplanin, this activity is observed at concentrations between 50–200 fold what is required for activity against sensitive bacteria.

The dimethyl ether derivative **10** did exhibit an increased binding affinity for D-Ala-D-Ala (ligand **3**, 0.5 kcal/mol) as projected by the computational studies (1.2 kcal/mol),¹¹ but it did not improve the affinity for D-Ala-D-Lac (ligand **4**) as projected (1.7 kcal/mol).¹¹ Overall the binding affinities for either D-Ala-D-Ala or D-Ala-D-Lac were relatively unaffected by the methylation state of the phenols, and do not correspond to the relative behavior of the compounds in the antimicrobial assays. The computations were correct in predicting modest effects on binding for most of the methylations, the outcome of which is not obvious due to the substantial changes in hydrogen bonding that accompany conversion of an alcohol to an ether.

Although there are several explanations that could account for this behavior and there are several ways to represent the trends in antimicrobial activity, one feature that stands out is the simple extent, not specific site, of methylation. This seemingly small change in the structures has a pronounced effect on the hydrophobic character of the compounds as judged by the chromatographic behavior (see the supporting information). For sensitive *S. aureus*, the marked changes in their activity may indicate a parabolic relationship with hydrophilic/hydrophobic character where the intermediate character (partial phenol methylation) is detrimental to antimicrobial activity, but either hydrophilic or the most hydrophobic derivatives are effective (Figure 6).

Extending this to an interpretation of the resistant VanB *E. faecalis* results only requires that the organism remain sensitive to the hydrophobic vancomycin aglycon derivatives, but lose their sensitivity to the hydrophilic derivatives and those of intermediate hydrophilic character (40–100 fold). Finally, only the most hydrophobic derivative **6** retains activity against resistant VanA *E. faecalis*, albeit at a reduced level, whereas the other derivatives were inactive. The only exception to this latter trend was **13**, which was 200-fold less active against resistant VanA *E. faecalis* than sensitive *S. aureus*. A simple interpretation of this behavior is that such hydrophobic derivatives of vancomycin aglycon fail to effectively trigger the inducible resistance mechanism resulting in the switch of peptidoglycan precursor from D-Ala-D-Ala to D-Ala-D-Lac. Evidence has been disclosed to indicate that this sensing of the glycopeptide challenge can arise from cell surface receptor recognition of either the antibiotic itself¹⁷ or the build-up of a bacterial cell wall biosynthetic intermediate¹⁸ by a two-component signaling pathway. Independent of the mechanism, the results herein suggest that the hydrophobic permethylated vancomycin aglycon derivatives, and the related teicoplanin and ristocetin aglycon methyl ethers,⁷ act by binding to D-Ala-D-Ala, fail to induce the resistance pathway resulting in D-Ala-D-Lac peptidoglycan generation, and serve as a distinct class of glycopeptide antibiotics effective against resistant bacteria.

The derivatives disclosed herein that display consistent activity against both sensitive and resistant VanB and VanA bacteria lack the lipophilic side chain found in teicoplanin (membrane anchoring effect) and the chlorobiphenyl dissacharide of **8** that may contribute to transglycosylase (vs transpeptidase) inhibition. We have speculated that the success of the derivatives is directly related to their hydrophobic character and their ability to penetrate the bacterial cell membrane sufficiently to avoid induction of the two component signaling pathway responsible for initiating and maintaining the remodeling of the peptidoglycan precursor from D-Ala-D-Ala to D-Ala-D-Lac. We have suggested that **6** and **7** act by the same mechanism as vancomycin (binds D-Ala-D-Ala), but at different physical sites in the bacterial cell wall (intra membrane rather than at the cell surface) potentially avoiding recognition by the two component signaling system or leading to the build up of a different, earlier bacterial cell wall precursor. Regardless of the mechanism, further studies with such derivatives may help define additional mechanisms for avoiding the induction or emergence of bacterial resistance.

Conclusions

We have reported the first stepwise substitution of the four phenols of vancomycin aglycon, defining a rank-order alkylation and indicating each phenol has a distinct reactivity, that was used to prepare a series of key partially methylated derivatives of the vancomycin aglycon. This series was utilized to further define the contribution methyl substitution of the phenols makes in a unique series of glycopeptide antibiotic derivatives that are active against vancomycin sensitive and resistant bacteria.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the financial support of the National Institutes of Health (CA144333, JGP; CA041101, DLB; GM032136, WLJ) and the Skaggs Institute for Chemical Biology.

References

1. For reviews, see: (a) Kahne D, Leimkuhler C, Lu W, Walsh CT. Glycopeptide and Lipoglycopeptide Antibiotics. *Chem Rev.* 2005; 105:425–428. [PubMed: 15700951] (b) Hubbard BK, Walsh CT. Vancomycin Assembly: Nature's Way. *Angew Chem, Int Ed.* 2003; 42:730–765. (c) Williams DH, Bardsley B. The Vancomycin Group of Antibiotics and the Fight Against Resistant Bacteria. *Angew Chem, Int Ed.* 1999; 38:1172–1193. (d) Malabarba A, Nicas TI, Thompson RC. Structural Modifications of Glycopeptide Antibiotics. *Med Res Rev.* 1997; 17:69–137. [PubMed: 8979249] For emerging vancomycin resistance in *S. aureus* see: (e) Tenover FC, Biddle JW, Lancaster MV. Increasing Resistance to Vancomycin and Other Glycopeptides in *Staphylococcus aureus*. *Emerg Infect Dis.* 2001; 7:327–332. [PubMed: 11294734] (f) Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM. *Staphylococcus aureus* with Reduced Susceptibility to Vancomycin Isolated from a Patient with Fatal Bacteremia. *Emerg Infect Dis.* 1999; 5:147–149. [PubMed: 10081683]
2. For reviews on glycopeptide resistance, see: (a) Malabarba A, Ciabatti R. Glycopeptide Derivatives. *Curr Med Chem.* 2001; 8:1759–1773. [PubMed: 11562292] (b) Pootoolal J, Neu J, Wright GD. Glycopeptide Antibiotic Resistance. *Annu Rev Pharmacol Toxicol.* 2002; 42:381–408. [PubMed: 11807177] (c) Van Bambeke FV, Laethem YV, Courvalin P, Tulkens PM. Glycopeptide Antibiotics: from Conventional to New Derivatives. *Drugs.* 2004; 64:913–1028. [PubMed: 15101783] (d) Süssmuth RD. Vancomycin Resistance: Small Molecule Approaches Targeting the Bacterial Cell Wall Biosynthesis. *ChemBioChem.* 2002; 3:295–298. [PubMed: 11933229] (e) Gao Y. Glycopeptide Antibiotics and Development of Inhibitors to Overcome Vancomycin Resistance. *Nat Prod Rep.* 2002; 19:100–107. [PubMed: 11902437] (f) Healy VL, Lessard IA, Roper DI, Knox JR, Walsh CT. Vancomycin Resistance in Enterococci: Reprogramming of the D-Ala-D-Ala Ligases in Bacterial Peptidoglycan Biosynthesis. *Chem Biol.* 2000; 7:R109–R119. [PubMed: 10801476] (g) Walker S, Chen L, Helm J, Hu Y, Rew Y, Shin D, Boger DL. Chemistry and Biology of Ramoplanin: A Lipoglycopeptide with Potent Antibiotic Activity. *Chem Rev.* 2005; 105:449–476. [PubMed: 15700952] (h) von Nussbaum F, Brands M, Hinzen B, Weigand S, Häbich D. Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival. *Angew Chem, Int Ed.* 2006; 45:5072–5129. (i) Nicolaou KC, Chen JS, Edmonds DJ, Estrada AA. Recent Advances in the Chemistry and Biology of Naturally Occurring Antibiotics. *Angew Chem, Int Ed.* 2009; 48:660–719.
3. McComas CC, Crowley BM, Boger DL. Partitioning the Loss in Vancomycin Binding Affinity for D-Ala-D-Lac into Lost H-Bond and Repulsive Lone Pair Contributions. *J Am Chem Soc.* 2003; 125:9314–9315. [PubMed: 12889959]
4. (a) Crowley BM, Boger DL. Total Synthesis and Evaluation of $[\Psi(\text{CH}_2\text{NH})\text{Tpg}^4]\text{Vancomycin}$ Aglycon: Reengineering Vancomycin for Dual D-Ala-D-Ala and D-Ala-D-Lac Binding. *J Am Chem Soc.* 2006; 128:2885–2892. [PubMed: 16506767] For related synthetic efforts, see: (b) Boger DL, Borzilleri RM, Nukui S, Beresis RT. Synthesis of the Vancomycin CD and DE Ring Systems. *J Org Chem.* 1997; 62:4721–4736. (c) Boger DL, Miyazaki S, Kim SH, Wu JH, Loiseleur O, Castle SL. Diastereoselective Total Synthesis of the Vancomycin Aglycon with Ordered Atropisomer Equilibrations. *J Am Chem Soc.* 1999; 121:3226–3227. (d) Boger DL, Miyazaki S, Kim SH, Wu JH, Castle SL, Loiseleur O, Jin Q. Total Synthesis of the Vancomycin Aglycon. *J Am Chem Soc.* 1999; 121:10004–10011. (e) Boger DL, Kim SH, Miyazaki S, Strittmatter H, Weng JH, Mori Y, Rogel O, Castle SL, McAtee JJ. Total Synthesis of the Teicoplanin Aglycon. *J Am Chem Soc.* 2000; 122:7416–7417. (f) Boger DL, Kim SH, Mori Y, Weng JH, Rogel O, Castle SL, McAtee JJ. First and Second Generation Total Synthesis of the Teicoplanin Aglycon. *J Am Chem Soc.* 2001; 123:1862–1871. [PubMed: 11456806] (g) Crowley BM, Mori Y, McComas CC, Tang D, Boger

- DL. Total Synthesis of the Ristocetin Aglycon. *J Am Chem Soc.* 2004; 126:4310–4317. [PubMed: 15053621] (h) Boger DL. Vancomycin, Teicoplanin, and Ramoplanin: Synthetic and Mechanistic Studies. *Med Res Rev.* 2001; 21:356–381. [PubMed: 11579438] (i) Garfinkle J, Kimball FS, Trzupek JD, Takazawa S, Shimamura H, Tomishima M, Boger DL. Total Synthesis of Chloropectin II (Complestatin) and Chloropectin I. *J Am Chem Soc.* 2009; 131:16036–16038. [PubMed: 19839632] (j) Shimamura H, Breazzano SP, Garfinkle J, Kimball FS, Trzupek JD, Boger DL. Total Synthesis of Complestatin, Development of a Pd(0)-Mediated Indole Annulation for Macrocyclization. *J Am Chem Soc.* 2010; 132:7776–7783. [PubMed: 20469945]
5. Oritavancin (LY333328), a further glycosylated analogue of chlorobiphenyl vancomycin, is under development for the treatment patients with serious bacterial infections. For a leading reference, see: Allen NE, Nicas TI. Mechanism of Action of Oritavancin and Related Glycopeptide Antibiotics. *FEMS Microbiol Rev.* 2003; 26:511–532. [PubMed: 12586393]
 6. For references regarding mode of action of chlorobiphenyl vancomycin, see: (a) Goldman RC, Baizman ER, Longley CB, Branstrom AA. Chlorobiphenyl-desleucyl-vancomycin Inhibits the Transglycosylation Process Required for Peptidoglycan Synthesis in Bacteria in the Absence of Dipeptide Binding. *FEMS Microbiol Lett.* 2000; 183:209–214. [PubMed: 10675585] (b) Kerns R, Dong SD, Fukuzawa S, Carbeck J, Kohler J, Silver L, Kahne D. The Role of Hydrophobic Substituents in the Biological Activity of Glycopeptide Antibiotics. *J Am Chem Soc.* 2000; 122:12608–12609. (c) Kim SJ, Matsuoka S, Patti GJ, Schaefer J. Vancomycin Derivative with Damaged D-Ala-D-Ala Binding Cleft Binds to Cross-Linked Peptidoglycan in the Cell Wall of *Staphylococcus aureus*. *Biochemistry.* 2008; 47:3822–3831. [PubMed: 18302341]
 7. McComas CC, Crowley BM, Hwang I, Boger DL. Synthesis and Evaluation of Methyl Ether Derivatives of Vancomycin, Teicoplanin, and Ristocetin Aglycon Methyl Ethers. *Bioorg Med Chem Lett.* 2003; 13:2933–2936. [PubMed: 14611861]
 8. McAtee JJ, Castle SL, Jin Q, Boger DL. Synthesis and Evaluation of Vancomycin and Vancomycin Aglycon Analogues that Bear Modifications in the Residue 3 Asparagine. *Bioorg Med Chem Lett.* 2002; 12:1319–1322. [PubMed: 11965380]
 9. Residue 1 modifications, see: (a) Cristofaro MF, Beauregard DA, Yan H, Osborn NJ, Williams DH. Cooperativity Between Non-Polar and Ionic Forces in the Binding of Bacterial Cell Wall Analogues by Vancomycin in Aqueous Solution. *J Antibiot.* 1995; 48:805–810. [PubMed: 7592024] (b) Kahne DW, Walker SS, Silva DJ. Desleucyl Glycopeptide Antibiotics and Methods of Making Same. *WO 2000/59528 (US 2004/110665)* 2000 (c) Crane CM, Boger DL. Synthesis and Evaluation of Vancomycin Aglycon Analogues That Bear Modifications in the N-Terminal D-Leucyl Amino Acid. *J Med Chem.* 2009; 52:1471–1476. [PubMed: 19209892]
 10. Residue 3 modifications of teicoplanin, see: (a) Malabarba A, Ciabatti R, Kettenring J, Ferrari P, Vékey K, Bellasio E, Denaro M. Structural Modifications of the Active Site in Teicoplanin and Related Glycopeptides. 1. Reductive Hydrolysis of the 1,2- and 2,3-Peptide Bonds. *J Org Chem.* 1996; 61:2137–2150. (b) Malabarba A, Ciabatti R, Gerli E, Ripamonti F, Ferrari P, Colombo L, Olsufyeva EN, Pavlov AY, Reznikova MI, Lazhko EI, Preobrazhenskaya MN. Substitution of Amino Acids 1 and 3 in Teicoplanin Aglycon: Synthesis and Antibacterial Activity of Three First Non-natural Dalbaheptides. *J Antibiot.* 1997; 50:70–81. [PubMed: 9066769]
 11. (a) Leung SSF, Tirado-Rives J, Jorgensen WL. Vancomycin Analogs: Seeking to Improve Binding of D-Ala-D-Ala and D-Ala-D-Lac Peptides by Side-chain and Backbone Modifications. *Bioorg Med Chem.* 2009; 17:5874–5886. [PubMed: 19620008] (b) Leung SSF, Tirado-Rives J, Jorgensen WL. Vancomycin Resistance: Modeling Backbone Variants with D-Ala-D-Ala and D-Ala-D-Lac Peptides. *Bioorg Med Chem Lett.* 2009; 19:1236–1239. [PubMed: 19128968]
 12. For references regarding the activity of oritavancin against the present strains of vancomycin sensitive *S. aureus* ATCC 25923 see: (a) Seral C, Van Bambeke F, Tulkens PM. Quantitative Analysis of Gentamycin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities Against *Staphylococcus aureus* in Mouse J774 Macrophages. *Antimicrob Agents Chemother.* 2003; 47:2283–2292. [PubMed: 12821480] (b) Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against *Staphylococcus aureus* in a Model of THP-1 Macrophages. *Antimicrob Agents Chemother.* 2006; 50:841–851. [PubMed: 16495241] For the activity of oritavancin against vancomycin resistant *E. faecalis* VanB strain ATCC 51299, see: (c) McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G. Time-kill Kinetics of

- Oritavancin and Comparator Agents against *Staphylococcus aureus*, *Enterococcus faecalis* and *Enterococcus faecium*. *J Antimicrob Chemother.* 2009; 63:1191–1199. [PubMed: 19369269] For the activity of oritavancin against vancomycin and teicoplanin resistance VanA strain BM4166, see: (d) Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-Level Resistance to Glycopeptide LY333328 Mediated by Genes of the vanA and vanB Clusters in Enterococci. *Antimicrob Agents Chemother.* 1999; 43:1875–1880. [PubMed: 10428906]
13. (a) Sharman GJ, Try AC, Dancer RJ, Cho YR, Staroske T, Bardsley B, Maguire AJ, Cooper MA, O'Brien DP, Williams DH. The Roles of Dimerization and Membrane Anchoring in Activity of Glycopeptide Antibiotics Against Vancomycin-Resistant Bacteria. *J Am Chem Soc.* 1997; 119:12041–12047. For a review, see: (b) Williams DH, Searle MS, Westwell MS, Mackay JP, Groves P, Beauregard DA. The Role of Weak Interactions, Dimerization, and Cooperativity in Antibiotic Action and Biological Signaling. *Chemtracts: Org Chem.* 1994; 7:133–159.
14. (a) Ge M, Chen Z, Onishi HR, Kohler J, Silver LL, Kerns R, Fukuzawa S, Thompson C, Kahne D. Vancomycin Derivatives that Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala. *Science.* 1999; 284:507–511. [PubMed: 10205063] (b) Chen L, Walker D, Sun B, Hu Y, Walker S, Kahne D. Vancomycin Analogs Active Against VanA-resistant Strains Inhibit Bacterial Transglycosylase Without Binding Substrate. *Proc Natl Acad Sci USA.* 2003; 100:5658–5663. [PubMed: 12714684]
15. For the TFA-mediated deglycosylation of vancomycin, see: (a) Boger DL, Miyazaki S, Loiseleur O, Beres RT, Castle SL, Wu JH, Jin Q. Thermal Atropisomerism of Aglucovancomycin Derivatives Preparation of (*M,M,M*)- and (*P,P,P*)-Aglucovancomycins. *J Am Chem Soc.* 1998; 120:8920–8926. (b) Wanner J, Tang D, McComas CC, Crowley BM, Jiang W, Moss J, Boger DL. A New and Improved Method for Deglycosylation of Glycopeptide Antibiotics Exemplified with Vancomycin, Ristocetin, and Ramoplanin. *Bioorg Med Chem Lett.* 2003; 13:1169–1173. [PubMed: 12643936]
16. UV-difference titration assays were run as previously described: (a) Nieto M, Perkins HR. The Specificity of Combination between Ristocetins and Peptides Related to Bacterial Cell Wall Muropeptide Precursors. *Biochem J.* 1971; 124:845–852. [PubMed: 4331859] (b) Nieto M, Perkins HR. Physicochemical Properties of Vancomycin and Iodovancomycin and their Complexes with Diacetyl-L-lysyl-D-alanyl-D-alanine. *Biochem J.* 1971; 123:773–787. [PubMed: 5124385] (c) Perkins HR. Specificity of Combination between Muropeptide Precursors and Vancomycin or Ristocetin. *Biochem J.* 1969; 111:195–205. [PubMed: 5763787]
17. For lead reference see: Koteva K, Hong HJ, Wang XD, Nazi I, Hughes D, Naldrett MJ, Buttner MJ, Wright GD. A Vancomycin Photoprobe Identifies the Histidine Kinase VanS as a Vancomycin Receptor. *Nat Chem Biol.* 2010; 6:327–329. [PubMed: 20383152]
18. For lead reference see: Hong H-J, Hutchings MI, Buttner MJ. Vancomycin Resistance VanS/VanR Two-Component Systems. *Adv Exp Med Biol.* 2008; 631:200–213. [PubMed: 18792691]

Figure 1. Schematic representation of the interactions between vancomycin (1), vancomycin aglycon (2), and model ligands *N,N'*-Ac₂-L-Lys-D-Ala-D-Ala (3) and *N,N'*-Ac₂-L-Lys-D-Ala-D-Lac (4).

Figure 3.
Analogues of vancomycin aglycon.

MIC, $\mu\text{g/mL}$	<i>S. aureus</i>	<i>E. faecalis</i> VanB	<i>E. faecalis</i> VanA
vancomycin (1)	1	>100	>100
aglycon (2)	0.6	>100	>100
6	1.3	2.5	80
7	1.6	1.6	40
8	0.03	0.03	10
teicoplanin (9)	0.2	0.2	>100

Figure 4.
Antimicrobial activity.

Figure 5. Diagnostic NOE cross-peaks for a) **16** and b) **17** in 100% DMSO- d_6 .

Figure 6. Bar graph representation of antimicrobial properties for compounds tested. (a) Against *S. aureus*. (b) Against *E. faecalis* (VanB). (c) Against *E. faecalis* (VanA).

Scheme 1.

Scheme 2.

Scheme 3.

Scheme 4.

Table 1

Antimicrobial Properties

Compound	MIC (μg/mL)		
	<i>S. aureus</i> ^a	<i>E. faecalis</i> ^b (VanA)	<i>E. faecalis</i> ^c (VanB)
1	1.25 (1.25) ^e	2000 (2000) ^e	120 (125) ^{d,e}
2	1.25 (0.625–1.25) ^{d,e}	640 (640) ^{d,e}	40 (80) ^d
6	1.25 (0.625) ^d	80 (40) ^d	2.5
7	1.25 (0.625–1.6) ^d	40 (40–50) ^d	1.25 (1.6–10) ^d
10	10	640	120
11	10	640	120
12	5	640	10
13	1.25	240	40

^a Vancomycin-sensitive *Staphylococcus aureus* (strain ATCC 25923).

^b Vancomycin-resistant *Enterococci faecalis* (VanA, strain BM4166).

^c Vancomycin-resistant *Enterococci faecalis* (VanB, strain ATCC 51299).

^d Taken from ref 7–8.

^e Taken from ref 4.

Table 2

Binding Properties

Compound	Association Constants (K_a , M^{-1})		$^c \Delta\Delta G_b^{obs}$ ($^d \Delta\Delta G_b^{cal}$, kcal/mol)	
	3^a ($\times 10^5$)	4^b ($\times 10^2$)	3^a	4^b
2	1.7 (1.7) ^e	1.2 (1.2–2.0) ^{e,f}	0.0 (0.0) ^d	4.3 (n.d.)
6	1.8 (1.4) ^f	1.1 (1.6) ^f	0 (1.0±0.7) ^d	4.4 (3.9±0.6) ^d
10	4.3	1.2	−0.5 (−1.2±0.4) ^d	4.4 (2.7±0.4) ^d
11	1.7	1.0	0 (n.d.)	4.5 (n.d.)
12	1.6	1.1	0.1 (1.0±0.7) ^d	4.4 (3.6±0.5) ^d
13	1.8	1.0	0 (n.d.)	4.5 (n.d.)

^a N,N' -Ac2-L-Lys-D-Ala-D-Ala.

^b N,N' -Ac2-L-Lys-D-Ala-D-Lac.

^c The free energy of binding ($\Delta\Delta G_b$) was tabulated from the experimentally determined K_a 's using the equation $\Delta\Delta G_b = RT \ln K$, where $K = {}^1K_a/{}^xK_a$; 1K_a is the association constant for the complex of **2** (taken from ref. ⁴ only) and ligand **3**; xK_a is the association constant for the complex of compound X with ligand of interest, see reference ¹¹.

^d Taken from ref. ¹¹.

^e Taken from ref. ⁸.

^f Taken from ref ⁴. n.d. = not computationally determined.